[시장보고서]세계의 방사선 독성 치료 시장(2023-2030년)

세계의 방사선 독성 치료 시장(2023-2030년)

Global Radiation Toxicity Treatment Market - 2023-2030

상품코드 : 1345398

리서치사 : DataM Intelligence

발행일 : 2023년 09월

페이지 정보 : 영문 195 Pages

라이선스 & 가격 (부가세 별도)

US $ 4,350

￦ 6,076,000

PDF & Excel (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 4,850

￦ 6,774,000

PDF & Excel (Multiple User License)

PDF 보고서를 동일 사업장에서 7명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 7,850

￦ 10,965,000

PDF & Excel (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

개요

세계의 방사선 독성 치료 시장은 2022년에 29억 달러에 달했으며, 2023-2030년의 예측 기간에 CAGR 6.1%로 성장하며, 2030년에는 46억 달러에 달할 것으로 예측되고 있습니다. 방사선 독성 치료 시장은 암 발병률 증가, 고령화 인구 증가, 정부 구상 등의 요인에 의해 주도되고 있습니다. 이온화 방사선 노출이 건강에 미치는 영향은 방사선 독성 치료를 구성합니다. 치료 방법은 방사선 노출 정도, 특정 증상 및 문제의 심각성에 따라 결정됩니다.

증상을 관리하고 환자의 전반적인 건강을 유지하는 것이 최우선 과제입니다. 여기에는 메스꺼움, 구토, 설사 등의 문제 해결, 통증 관리, 상처 관리 등이 포함됩니다. 방사선 노출과 치료 시작 사이의 간격에 따라 치료의 효율성이 영향을 받을 수 있습니다. 조기 개입을 통해 일부 영향을 막거나 완화할 수 있습니다.

환자의 치료 선택은 의료 시설, 전문 치료법, 약품, 의료진의 접근성 여부에 따라 달라집니다. 방사선 민감도는 다양한 조직과 기관에 따라 다릅니다. 치료 계획은 여러 문제 부위를 대상으로 특별히 설계됩니다. 방사선 독성 및 관련 치료법에 대한 지속적인 연구로 새로운 치료 접근법과 개입이 개발될 수 있습니다.

시장 역학

암 발병률 증가는 세계 방사선 독성 치료 시장의 성장을 주도하고 있습니다.

방사선 치료의 필요성은 세계 암 발병률 증가로 인해 부작용을 관리할 수 있는 효율적인 방사선 독성 치료에 대한 욕구를 지원하고 있습니다. 이환율에 변화가 없고 인구 증가와 고령화가 현재 추세대로 진행된다면, 2040년까지 연간 2,800만 명의 새로운 암 환자가 발생할 것으로 추정됩니다. 이는 2020년 대비 54.9% 증가한 수치이며, 남자아이(60.6%)가 여자아이(48.8%)보다 더 많이 증가할 것으로 예상됩니다.

음주, 수면 부족, 흡연, 비만, 고도로 가공된 음식 섭취는 모두 조기 암 발병의 잠재적 위험 요소였습니다. 놀랍게도 성인의 수면 시간은 수년 동안 크게 변하지 않았음에도 불구하고 청소년의 수면 시간은 수십년전보다 훨씬 더 짧아진 것으로 나타났습니다.

고령화 인구 증가로 세계 방사선 독성 치료 시장 성장 촉진

일반적인 암은 나이가 들어감에 따라 발병할 수 있으며, 치료 과정에서 방사선 독성이 발생할 수 있습니다. 연구에 따르면 노인(65세 이상으로 정의)은 젊은 사람보다 암에 걸릴 위험이 11배 더 높다고 합니다. 세계 인구의 고령화로 인해 향후 20년간 노인의 암 발병률은 증가할 것으로 예상됩니다.

노화는 암의 위험 요인으로 잘 알려져 있으며, 암 진단 건수를 증가시킬 수 있습니다. 암 진단과 암으로 인한 사망의 대부분은 65세 이상에서 발생합니다. 이러한 증가하는 공중보건 문제에 대해 많은 준비가 필요합니다. 고령의 암 환자 및 암 생존자의 요구에 대한 철저한 접근 방식을 제공하기 위해 이 분야에서 더 많은 연구가 이루어져야 합니다.

방사선 독성 치료의 과제는 세계 방사선 독성 치료 시장의 성장을 저해하는 요인으로 작용합니다.

환자와 의료진 사이에서 방사선 독성 치료의 이점에 대한 지식이 부족하다는 점이 시장 성장을 저해할 수 있습니다. 새로운 방사선 보호 약물 및 치료법에 대한 규제 당국의 승인 절차는 시간과 비용이 많이 들기 때문에 혁신적인 품목 시장 출시가 늦어질 수 있습니다. 방사선 독성 치료는 개발 및 판매에 비용이 많이 들기 때문에 지역과 의료 시스템에 따라 환자의 접근성이 제한될 수 있습니다.

영문목차

Overview

The Global Radiation Toxicity Treatment Market reached US$ 2.9 billion in 2022 and is expected to reach US$ 4.6 billion by 2030 growing with a CAGR of 6.1% during the forecast period 2023-2030. The radiation toxicity treatment market is driven by factors such as increasing cancer incidence, rising aging population and government initiatives. The health consequences of exposure to ionizing radiation constitutes radiation toxicity treatment. The method of treatment is determined by the degree of radiation exposure, the particular symptoms, and the seriousness of the problem.

Managing symptoms and preserving the patient's general health are the major priorities. This may involve dealing with concerns including nausea, vomiting, and diarrhea as well as managing pain and taking care of open wounds.The efficiency of interventions can be impacted by the interval between radiation exposure and the start of therapy. Early intervention may stop or lessen some effects.

The treatment options of a patient will be dependent on the accessibility of medical facilities, specialist therapies, drugs, and healthcare personnel. Radiation sensitivity varies among various tissues and organs. Treatment plans will be specifically designed to target the many problematic areas. New therapeutic approaches and interventions may be developed as a result of ongoing study on radiation toxicity and related therapies.

Market Dynamics

The Increasing Cancer Incidence are Driving the Global Radiation Toxicity Treatment Market Growth

The need for radiation therapy is driven by the rising incidence of cancer worldwide, which in turn supports the desire for efficient radiation toxicity treatments to manage the side effects. If incidence stays unchanged and population growth and aging follow current trends, there will be an estimated 28 million new cancer cases annually by 2040. This represents an increase of 54.9% from 2020, and it is anticipated that males will have a greater increase (60.6%) than girls (48.8%).

Alcohol intake, sleep deprivation, smoking, obesity, and consuming highly processed foods were all potential risk factors for early-onset cancer. Surprisingly, researchers discovered that youngsters are getting far less sleep now than they did decades ago, despite the fact that adult sleep length hasn't changed significantly over the years.

The Increasing Aging Population Boost The Global Radiation Toxicity Treatment Market Growth

In population cancer may develop with age and its treatment radiation toxicity comes. According to research, older adults (defined as those 65 and older) had an 11 times higher risk of developing cancer than younger people. The burden of cancer among the elderly will increase during the next 20 years due to the aging of the world population.

Age is a well-known risk factor for cancer, which could lead to an increase in the number of cancer diagnoses. The bulk of cancer diagnoses and cancer deaths occur in people over 65. A lot of preparation is required for this expanding public health concern. To provide a thorough approach to the requirements of elderly cancer patients and survivors, more work must be done in this area.

Challenges with Radiation Toxicity Treatment are Hampering the Global Radiation Toxicity Treatment Market Growth

Growth of the market may be hampered by a lack of knowledge about the advantages of radiation toxicity therapies among patients and medical professionals. The introduction of innovative items to the market may be slowed back by the lengthy and expensive regulatory approvals process for new radioprotective medications and treatments. Radiation toxicity treatments may be expensive to develop and market, which may limit patient access in some areas or within particular healthcare systems.

Segment Analysis

The global radiation toxicity treatment market is segmented based on product, indication, radiation type, end-user and region.

The Acute Radiation Syndrome Segment is Expected to Hold a Dominant Position in the Market Over the Forecast Period

The acute radiation syndrome segment accounted for the highest market stake accounting for approximately 46.2% of the radiation toxicity treatment market in 2022. Cardiovascular illness and cancer frequently co-occur. Cardiovascular toxicities can be caused by chemotherapy, radiation therapy, and other cancer treatments. Coronary artery disease (CAD), valvular heart disease (VHD), heart failure (HF), myocarditis, cardiomyopathies, arrhythmias, and acute and chronic pericardial syndromes may all be brought on by radiation treatment.

Cardiotoxicities brought on by radiation therapy are caused by a variety of processes. The interval between radiation therapy exposure and the onset of cardiac toxicities, as well as the radiation dose to which the heart is exposed, are additional crucial factors. While some cardiac toxicities, such as pericardial effusion or acute pericarditis, arrhythmic events, and conduction abnormalities, can manifest right away after the start of radiotherapies, others, like coronary artery disease, valvular heart disease, chronic pericardial syndromes, and constriction, can take years to manifest.

Geographical Penetration

North America Holds a Dominant Position in the Global Radiation Toxicity Treatment Market

North America is holding around 38.8% of the total market share in 2022. As of October 2022, the acute radiation syndrome (ARS)-related blood cell damage that Nplate from Amgen treats in both children and adults will cost the U.S. Department of Health and Human Services (HHS) an undisclosed amount of money to lock up. When a person's body is subjected to a high dose of penetrating radiation, which is capable of "reaching internal organs in a matter of seconds,", is also known as radiation sickness.

Competitive Landscape

The major global players in the market include: Amgen, Jubilant Pharma Limited, Tanner Pharma Group, Heyl Chemisch-pharmazeutische Fabrik GmbH & Co. KG, Recipharm AB, Mission Pharmacal Company, Partner Therapeutics, Inc., Novartis AG, Mylan NV, and Coherus Biosciences Inc. among others.

COVID-19 Impact Analysis

Russia-Ukraine Conflict Analysis

The Russia-Ukraine war may affect the radiation toxicity treatment market due to a lack of facilities being impacted during times of geopolitical instability and economic uncertainty. Resources and attention may be diverted away from research and development projects in the healthcare industry, particularly radiation toxicity therapy, during times of conflict or war.

Artificial Intelligence Analysis:

Artificial intelligence (AI) is increasingly being used in the radiation toxicity treatment market to improve various aspects of data analysis. Radiomics is the study of quantitative features extracted and analyzed from medical pictures. Based on the particular characteristics of a patient's anatomy, AI-driven radiomics may forecast the likelihood of radiation damage. This knowledge can direct medical decisions and assist practitioners in identifying patients who could be more vulnerable to toxicity.

By Treatment

Colony Stimulating Factors
Potassium Iodide
Prussian Blue
Diethylenetriamine Pentaacetic Acid
Others

By Indication

Acute Radiation Syndrome
- Bone Marrow Syndrome
- Gastrointestinal Syndrome
- Cardiovascular syndrome

Chronic Radiation Syndrome

By Radiation Type

Ionizing Radiation
- Alpha Radiation
- Beta Radiation
- Gamma Radiation

Non-ionizing Radiation

By End-user

Hospitals
Specialty Clinics
Others

By Region

North America
- U.S.
- Canada
- Mexico

Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Rest of Europe

South America
- Brazil
- Argentina
- Rest of South America

Asia-Pacific
- China
- India
- Japan
- Australia
- Rest of Asia-Pacific

Middle East and Africa

Key Developments

In March 2023, Coherus BioSciences, Inc. reported that The U.S. Food and Drug Administration approved UDENYCA (pegfilgrastim-cbqv), a biosimilar pegfilgrastim that is given the day after chemotherapy to lessen the likelihood of infection as seen by febrile neutropenia. The UDENYCA autoinjector has a simple, user-friendly design that makes it suitable for usage in both in-office and at-home care settings. It is indicated to patients who receive radiation doses that are myelosuppressive in nature are more likely to survive (Hematopoietic Subsyndrome of Acute Radiation Syndrome).

Why Purchase the Report?

To visualize the global radiation toxicity treatment market segmentation based on the product, indication, radiation type, end-user and region and understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of radiation toxicity treatment market-level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping available as excel consisting of critical products of all the major players.

The global radiation toxicity treatment market report would provide approximately 69 tables, 69 figures, and 195 Pages.

Target Audience 2023

Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Product
3.2. Snippet by Indication
3.3. Snippet by Radiation Type
3.4. Snippet by End-user
3.5. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Rising cancer incidence
- 4.1.2. Restraints
  - 4.1.2.1. Challenges associated with radiation toxicity treatment
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Unmet Needs
5.4. Regulatory Analysis

6. COVID-19 Analysis

6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID-19
- 6.1.2. Scenario During COVID-19
- 6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers' Strategic Initiatives
6.6. Conclusion

7. Russia-Ukraine War Analysis

8. Artificial Intelligence Analysis

9. By Product

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 9.1.2. Market Attractiveness Index, By Product
9.2. Colony Stimulating Factors*
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Potassium Iodide
9.4. Prussian Blue
9.5. Diethylenetriamine Pentaacetic Acid
9.6. Others

10. By Indication

10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
- 10.1.2. Market Attractiveness Index, By Indication
10.2. Acute Radiation Syndrome*
- 10.2.1. Introduction
- 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 10.2.3. Bone Marrow Syndrome
- 10.2.4. Gastrointestinal Syndrome
- 10.2.5. Cardiovascular syndrome
10.3. Chronic Radiation Syndrome

11. By Radiation Type

11.1. Introduction
- 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Radiation Type
- 11.1.2. Market Attractiveness Index, By Radiation Type
- 11.1.3. Ionizing Radiation*
- 11.1.4. Introduction
- 11.1.5. Market Size Analysis and Y-o-Y Growth Analysis (%)
  - 11.1.5.1. Alpha Radiation
  - 11.1.5.2. Beta Radiation
  - 11.1.5.3. Gamma Radiation
- 11.1.6. Non-ionizing Radiation

12. By End-user

12.1. Introduction
- 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
- 12.1.2. Market Attractiveness Index, By End-user
- 12.1.3. Hospitals*
  - 12.1.3.1. Introduction
  - 12.1.3.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 12.1.4. Specialty Clinics
- 12.1.5. Others

13. By Region

13.1. Introduction
- 13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 13.1.2. Market Attractiveness Index, By Region
13.2. North America
- 13.2.1. Introduction
- 13.2.2. Key Region-Specific Dynamics
- 13.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 13.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
- 13.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Radiation Type
- 13.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
- 13.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 13.2.7.1. U.S.
  - 13.2.7.2. Canada
  - 13.2.7.3. Mexico
13.3. Europe
- 13.3.1. Introduction
- 13.3.2. Key Region-Specific Dynamics
- 13.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 13.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
- 13.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Radiation Type
- 13.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
- 13.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 13.3.7.1. Germany
  - 13.3.7.2. U.K.
  - 13.3.7.3. France
  - 13.3.7.4. Italy
  - 13.3.7.5. Spain
  - 13.3.7.6. Rest of Europe
13.4. South America
- 13.4.1. Introduction
- 13.4.2. Key Region-Specific Dynamics
- 13.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 13.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
- 13.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Radiation Type
- 13.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
- 13.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 13.4.7.1. Brazil
  - 13.4.7.2. Argentina
  - 13.4.7.3. Rest of South America
13.5. Asia-Pacific
- 13.5.1. Introduction
- 13.5.2. Key Region-Specific Dynamics
- 13.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 13.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
- 13.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Radiation Type
- 13.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
- 13.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 13.5.7.1. China
  - 13.5.7.2. India
  - 13.5.7.3. Japan
  - 13.5.7.4. Australia
  - 13.5.7.5. Rest of Asia-Pacific
13.6. Middle East and Africa
- 13.6.1. Introduction
- 13.6.2. Key Region-Specific Dynamics
- 13.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 13.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
- 13.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Radiation Type
- 13.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user

14. Competitive Landscape

14.1. Competitive Scenario
14.2. ProductBenchmarking
14.3. Company Share Analysis
14.4. Key Developments and Strategies

15. Company Profiles

15.1. Amgen*
- 15.1.1. Company Overview
- 15.1.2. Product Portfolio and Description
- 15.1.3. Financial Overview
- 15.1.4. Key Developments
15.2. Jubilant Pharma Limited
15.3. Tanner Pharma Group
15.4. Heyl Chemisch-pharmazeutische Fabrik GmbH & Co. KG
15.5. Recipharm AB
15.6. Mission Pharmacal Company
15.7. Partner Therapeutics, Inc.
15.8. Novartis AG
15.9. Mylan NV
15.10. Coherus Biosciences Inc.

LIST NOT EXHAUSTIVE

16. Appendix

16.1. About Us and Services
16.2. Contact Us